Table 3

Total number and per cent (n/%) of participants reporting swelling, erythema or induration after Tdap injection

Swelling (N=793)Erythema (N=793)Induration* (N=326)
None733 (92.4)747 (94.2)287 (88.0)
Circumference of event (cm)(n=60)(n=46)(n=39)
 >0.0 to <1.033 (4.2)25 (3.2)21 (6.4)
 >1.0 to <2.512 (1.5)10 (1.3)12 (3.7)
 >2.5 to <5.012 (1.5)8 (1.0)6 (1.8)
 >5.0 to <10.02 (0.3)3 (0.4)
 >10.0 to <15.01 (0.1)
Onset of event after injection (h)(n=60)(n=46)(n=39)
 0–2444 (73.3)27 (58.7)15 (38.5)
 25–4816 (26.7)16 (34.8)22 (56.4)
 >493 (6.5)2 (5.1)
Resolution of event (h)(n=60)(n=46)(n=39)
 0–2414 (23.3)13 (28.3)6 (15.4)
 25–4815 (25.0)10 (21.7)11 (28.2)
 >4931 (51.7)23 (50.0)22 (56.4)
  • *Northern study data only.